Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids
International Journal of Molecular Sciences · 21.06.2023 · 24 (13) · 10465
DOI: 10.3390/ijms241310465 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.06.2023. Verfasst von Tsai-Der Chuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA. Hauptthemen laut MEDLINE: Transforming Growth Factor beta3, Leiomyoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Tranilast (N-3, 4-dimethoxycinnamoyl anthranilic acid) is an orally administered drug with antiallergic properties and approved in Japan and the Republic of Korea for the treatment of asthma and hypertrophic scars. Previous in vitro studies indicated that tranilast reduced fibroid growth through its inhibitory effects on cell proliferation and induction of apoptosis. The objective of this study was to determine the efficacy of tranilast for treatment of human-derived fibroids in a mouse model. SCID mice (ovariectomized, supplemented with estrogen and progesterone) were implanted with fibroid explants and treated for two months with tranilast (50 m/kg/daily) or the vehicle. After sacrifice, xenografts were excised and analyzed. Tranilast was well tolerated without adverse side effects. There was a 37% reduction in tumor weight along with a significant decrease in staining for Ki67, CCND1, and E2F1; a significant increase in nuclear staining for cleaved caspase 3; and reduced staining for TGF-β3 and Masson’s trichrome in the tranilast treated mice. There was a significant inhibition of mRNA and protein expression of fibronectin, COL3A1, CCND1, E2F1, and TGF-β3 in the xenografts from the tranilast-treated mice. These promising therapeutic effects of tranilast warrant additional animal studies and human clinical trials to evaluate its efficacy for treatment of fibroids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
- The Lundquist Institute for Biomedical Innovation, Torrance, CA 90502, USA.
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
ORCID-Profile: Tsai-Der Chuang, Leslie Munoz
Förderung
- NICHD NIH HHS
- National Institutes of Health
Zitieren
APA
Chuang, T. D., Munoz, L., Quintanilla, D., Boos, D., & Khorram, O. (2023). Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids. International Journal of Molecular Sciences, 24(13), 10465. https://doi.org/10.3390/ijms241310465
Vancouver
Chuang TD, Munoz L, Quintanilla D, Boos D, Khorram O. Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids. International Journal of Molecular Sciences. 2023;24(13):10465. doi:10.3390/ijms241310465
BibTeX
@article{Chuang2023,
author = {Chuang, Tsai-Der and Munoz, Leslie and Quintanilla, Derek and Boos, Drake and Khorram, Omid},
title = {Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {10465},
doi = {10.3390/ijms241310465}
}
EUVIMED